Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 209Stomach Neoplasms 37Neoplasm Metastasis 26Neoplasms 18HER2-positive Breast Cancer 14Colorectal Neoplasms 14Carcinoma, Non-Small-Cell Lung 10Brain Neoplasms 10Esophageal Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Urologic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3HER2-positive Gastric Cancer 3Carcinoma 3Breast Cancer Metastatic 3Urinary Bladder Neoplasms 2Solid Tumors 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Melanoma 2HER2-positive Early Breast Cancer 2Cholangiocarcinoma 2Breast Diseases 2

Interventions

Trastuzumab 3Docetaxel 3Gemcitabine 2tusamitamab ravtansine 1nirogacestat 1margetuximab 1exemestane 1Vinorelbine 1Tamoxifen 1Letrozole 1Fulvestrant 1Capecitabine 1Anastrozole 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Breast Cancer Metastatic × Trastuzumab × Clear all
NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Zai Lab (Hong Kong), Ltd.

Phase 2 Unknown
123 enrolled
Breast

Breast Cancer Metastatic

NCT05301010 2023-02-27

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 3 Completed
128 enrolled
Breast

Breast Cancer Metastatic

NCT05301530 2022-03-29

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 1 Completed
50 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡